{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:01:42Z","timestamp":1783605702699,"version":"3.55.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.biopha.2024.117468","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T23:53:57Z","timestamp":1727308437000},"page":"117468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Unveiling the antitumor synergy between pazopanib and metformin on lung cancer through suppressing p-Akt\/ NF-\u03baB\/ STAT3\/ PD-L1 signal pathway"],"prefix":"10.1016","volume":"180","author":[{"given":"Fatma M.","family":"Abdallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asser I.","family":"Ghoneim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad M.","family":"Abd\u2011Alhaseeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihab T.","family":"Abdel-Raheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maged W.","family":"Helmy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2024.117468_bib1","article-title":"Global Cancer Statistics 2022: the trends projection analysis","volume":"10","author":"Chhikara","year":"2023","journal-title":"Chem. Biol. Lett."},{"key":"10.1016\/j.biopha.2024.117468_bib2","series-title":"Abeloff's Clinical Oncology","first-page":"1108","article-title":"Cancer of the lung: non\u2013small cell lung cancer and small cell lung cancer","author":"Araujo","year":"2020"},{"key":"10.1016\/j.biopha.2024.117468_bib3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s12272-021-01312-y","article-title":"Mechanisms of resistance to chemotherapy in non-small cell lung cancer","volume":"44","author":"Min","year":"2021","journal-title":"Arch. Pharmacal Res."},{"issue":"1","key":"10.1016\/j.biopha.2024.117468_bib4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/07357900701662509","article-title":"Tumoral angiogenesis: review of the literature","volume":"26","author":"Shahi","year":"2008","journal-title":"Cancer Investig."},{"key":"10.1016\/j.biopha.2024.117468_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cancergen.2017.07.005","article-title":"Upregulation of vascular endothelial growth factor (VEGF), its role in progression and prognosis of non-small cell lung carcinoma","volume":"216","author":"Naikoo","year":"2017","journal-title":"Cancer Genet."},{"issue":"4","key":"10.1016\/j.biopha.2024.117468_bib6","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.cllc.2020.02.024","article-title":"The story of angiogenesis inhibitors in non\u2013small-cell lung cancer: the past, present, and future","volume":"21","author":"Shukla","year":"2020","journal-title":"Clin. lung Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2024.117468_bib7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/jjco\/hyy053","article-title":"Drug review: pazopanib","volume":"48","author":"Miyamoto","year":"2018","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.biopha.2024.117468_bib8","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1111\/1759-7714.14543","article-title":"Pazopanib restricts small cell lung cancer proliferation via reactive oxygen species-mediated endoplasmic reticulum stress","volume":"13","author":"Li","year":"2022","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.biopha.2024.117468_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122287","article-title":"Pazopanib-laden lipid based nanovesicular delivery with augmented oral bioavailability and therapeutic efficacy against non-small cell lung cancer","volume":"628","author":"Nadaf","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2024.117468_bib10","doi-asserted-by":"crossref","unstructured":"Sternberg, C.N., et al., Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. 2023.","DOI":"10.1200\/JCO.22.02622"},{"issue":"1","key":"10.1016\/j.biopha.2024.117468_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ol.2022.13325","article-title":"Metformin: a promising drug for human cancers","volume":"24","author":"Wu","year":"2022","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.biopha.2024.117468_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13402-020-00570-0","article-title":"Molecular mechanisms underlining the role of metformin as a therapeutic agent in lung cancer","volume":"44","author":"Fatehi Hassanabad","year":"2021","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.biopha.2024.117468_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109770","article-title":"STAT3 as a therapeutic target in the metformin-related treatment","volume":"116","author":"Zhang","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117468_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2018.07.030","article-title":"Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1","volume":"71","author":"Cha","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.biopha.2024.117468_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113787","article-title":"Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin","volume":"174","author":"Bahrambeigi","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117468_bib16","doi-asserted-by":"crossref","first-page":"10255","DOI":"10.1038\/s41598-017-10925-7","article-title":"PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.biopha.2024.117468_bib17","first-page":"1","article-title":"Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer","volume":"51","author":"Kim","year":"2019","journal-title":"Exp. Mol. Med."},{"issue":"4","key":"10.1016\/j.biopha.2024.117468_bib18","first-page":"800","article-title":"Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer","volume":"9","author":"Han","year":"2019","journal-title":"Am. J. Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2024.117468_bib19","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3390\/jcm9030675","article-title":"Combining immune checkpoint inhibitors with anti-angiogenic agents","volume":"9","author":"Ciciola","year":"2020","journal-title":"J. Clin. Med."},{"issue":"9","key":"10.1016\/j.biopha.2024.117468_bib20","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41419-023-06119-x","article-title":"Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications","volume":"14","author":"Fang","year":"2023","journal-title":"Cell Death Dis."},{"issue":"9","key":"10.1016\/j.biopha.2024.117468_bib21","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"23","key":"10.1016\/j.biopha.2024.117468_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13236033","article-title":"Pre-clinical in vitro models used in cancer research: results of a worldwide survey","volume":"13","author":"Martinez-Pacheco","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"s1","key":"10.1016\/j.biopha.2024.117468_bib23","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1017\/S0007114517002227","article-title":"The 3Rs in research: a contemporary approach to replacement, reduction and refinement","volume":"120","author":"Clark","year":"2018","journal-title":"Br. J. Nutr."},{"issue":"2","key":"10.1016\/j.biopha.2024.117468_bib24","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.biopha.2024.117468_bib25","first-page":"1","article-title":"Synergistic antiproliferative effects of curcumin and celecoxib in hepatocellular carcinoma HepG2 cells","author":"Abdallah","year":"2018","journal-title":"Naunyn-Schmiede's. Arch. Pharmacol."},{"key":"10.1016\/j.biopha.2024.117468_bib26","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2147\/IJN.S188335","article-title":"Liquid crystalline assembly for potential combinatorial chemo\u2013herbal drug delivery to lung cancer cells.","volume":"14","author":"Abdelaziz","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2024.117468_bib27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.colsurfb.2018.05.008","article-title":"Hyaluronate\/lactoferrin layer-by-layer-coated lipid nanocarriers for targeted co-delivery of rapamycin and berberine to lung carcinoma","volume":"169","author":"Kabary","year":"2018","journal-title":"Colloids Surf. B: Biointerfaces"},{"issue":"8","key":"10.1016\/j.biopha.2024.117468_bib28","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.3390\/molecules27082391","article-title":"Evening primrose oil enhances tamoxifen\u2019s anticancer activity against breast cancer cells by inducing apoptosis, inhibiting angiogenesis, and arresting the cell cycle","volume":"27","author":"Abd-Alhaseeb","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2024.117468_bib29","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1007\/s11033-021-06715-0","article-title":"Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K\/Akt\/mTOR\/NF-\u03baB and VEGF\/VEGFR2 signaling pathways","volume":"48","author":"El-Hanboshy","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.biopha.2024.117468_bib30","article-title":"Bradford protein assay","author":"He","year":"2011","journal-title":"Bio-Protoc."},{"issue":"1","key":"10.1016\/j.biopha.2024.117468_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/cpim.40","article-title":"Flow cytometry: an overview","volume":"120","author":"McKinnon","year":"2018","journal-title":"Curr. Protoc. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2024.117468_bib32","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.bbrc.2018.06.129","article-title":"The anti-tumor effect of regorafenib in lung squamous cell carcinoma in vitro","volume":"503","author":"Hu","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.biopha.2024.117468_bib33","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.prot077446","article-title":"Induction of lung tumors in mice with urethane","volume":"2015","author":"Gurley","year":"2015","journal-title":"Cold Spring Harb. Protoc."},{"issue":"2","key":"10.1016\/j.biopha.2024.117468_bib34","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1021\/acsbiomaterials.9b01639","article-title":"Inhalable lactoferrin\/chondroitin-functionalized monoolein nanocomposites for localized lung cancer targeting","volume":"6","author":"Abdelaziz","year":"2020","journal-title":"ACS Biomater. Sci. Eng."},{"issue":"3","key":"10.1016\/j.biopha.2024.117468_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2019.12.011","article-title":"Temozolomide and pazopanib combined with folfox regressed a primary colorectal cancer in a patient-derived orthotopic xenograft mouse model","volume":"13","author":"Zhu","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.biopha.2024.117468_bib36","article-title":"Metformin overcomes acquired resistance to EGFR TKIs in EGFR-mutant lung cancer via AMPK\/ERK\/NF-\u03baB signaling pathway","volume":"10","author":"Li","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2024.117468_bib37","article-title":"Metformin synergizes with PD-L1 monoclonal antibody enhancing tumor immune response in treating non-small cell lung cancer and its molecular mechanism investigation","volume":"2022","author":"Wang","year":"2022","journal-title":"Evid. - Based Complement. Altern. Med."},{"issue":"1","key":"10.1016\/j.biopha.2024.117468_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/0471142735.im0107s73","article-title":"Blood collection","volume":"73","author":"Donovan","year":"2006","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.biopha.2024.117468_bib39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.biopha.2018.09.016","article-title":"Chemopreventive and antitumor effects of benzyl isothiocynate on HCC models: A possible role of HGF \/pAkt\/ STAT3 axis and VEGF","volume":"108","author":"Zakaria","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2024.117468_bib40","unstructured":"Brito, C.Fd, et al., Laboratory Mice Euthanasia: Speed Death and Animal Welfare. 2020."},{"issue":"9","key":"10.1016\/j.biopha.2024.117468_bib41","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3858\/emm.2010.42.9.059","article-title":"TGF-\u03b21 induces mouse dendritic cells to express VEGF and its receptor (Flt-1) under hypoxic conditions","volume":"42","author":"Nam","year":"2010","journal-title":"Exp. Mol. Med."},{"issue":"2","key":"10.1016\/j.biopha.2024.117468_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004871","article-title":"Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects","volume":"11","author":"Bai","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2024.117468_bib43","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212 \u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.biopha.2024.117468_bib44","author":"Moussa","year":"2021","journal-title":"Dual-targeted nano-in-nano albumin carriers enhance the efficacy of combined chemo\/herbal therapy of lung cancer"},{"issue":"17","key":"10.1016\/j.biopha.2024.117468_bib45","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.2217\/nnm-2018-0097","article-title":"Dual-targeted nano-in-nano albumin carriers enhance the efficacy of combined chemo\/herbal therapy of lung cancer","volume":"13","author":"Elgohary","year":"2018","journal-title":"Nanomedicine"},{"issue":"13","key":"10.1016\/j.biopha.2024.117468_bib46","doi-asserted-by":"crossref","first-page":"37280","DOI":"10.1007\/s11356-022-24813-9","article-title":"The effect of Moringa oleifera leaf extracts against urethane-induced lung cancer in rat model","volume":"30","author":"Ibrahim","year":"2023","journal-title":"Environ. Sci. Pollut. Res."},{"key":"10.1016\/j.biopha.2024.117468_bib47","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.lfs.2018.10.002","article-title":"Inhibition of SRC\/FAK cue: a novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma","volume":"213","author":"El Sayed","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2024.117468_bib48","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s12672-018-0336-7","article-title":"Androgen receptor and Ki67 expression and survival outcomes in non-small cell lung cancer","volume":"9","author":"Grant","year":"2018","journal-title":"Horm. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2024.117468_bib49","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1293\/tox.2016-0066","article-title":"Immunohistochemical characterization of urethane-induced lung tumors in CB6F1-Tg rasH2 mice","volume":"30","author":"Sano","year":"2017","journal-title":"J. Toxicol. Pathol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117468_bib50","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.3892\/mmr.2016.5661","article-title":"Inflammation has a role in urethane\u2011induced lung cancer in C57BL\/6J mice.","volume":"14","author":"Xu","year":"2016","journal-title":"Mol. Med. Rep."},{"issue":"4","key":"10.1016\/j.biopha.2024.117468_bib51","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/10915810701483450","article-title":"A review of the histopathology of cigarette smoke\u2013induced lung cancer in rats and mice","volume":"26","author":"Hahn","year":"2007","journal-title":"Int. J. Toxicol."},{"issue":"11","key":"10.1016\/j.biopha.2024.117468_bib52","first-page":"1490","article-title":"Akt-dependent regulation of NF-\u03baB is controlled by mTOR and raptor in association with IKK","volume":"22","author":"Dan","year":"2008"},{"issue":"5","key":"10.1016\/j.biopha.2024.117468_bib53","first-page":"1107","article-title":"STAT3: versatile functions in non-small cell lung cancer","volume":"12","author":"Mohrherr","year":"2020"},{"issue":"12","key":"10.1016\/j.biopha.2024.117468_bib54","first-page":"2642","article-title":"Metformin synergistically enhances the antitumor activity of the third-generation EGFR-TKI CO-1686 in lung cancer cells through suppressing NF-\u03baB signaling","volume":"12","author":"Pan","year":"2018"},{"issue":"4","key":"10.1016\/j.biopha.2024.117468_bib55","first-page":"636","article-title":"Metformin suppresses pancreatic tumor growth with inhibition of NF\u03baB\/STAT3 inflammatory signaling","volume":"44","author":"Tan","year":"2015"},{"issue":"33","key":"10.1016\/j.biopha.2024.117468_bib56","doi-asserted-by":"crossref","first-page":"55230","DOI":"10.18632\/oncotarget.19420","article-title":"Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade","volume":"8","author":"Ishibashi","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.biopha.2024.117468_bib57","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5387\/fms.2018-15","article-title":"Interleukin-6 induces drug resistance in renal cell carcinoma","volume":"64","author":"Ishibashi","year":"2018","journal-title":"Fukushima J. Med. Sci."},{"issue":"42","key":"10.1016\/j.biopha.2024.117468_bib58","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1038\/sj.onc.1204833","article-title":"Biologic sequelae of interleukin-6 induced PI3-K\/Akt signaling in multiple myeloma","volume":"20","author":"Hideshima","year":"2001","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.biopha.2024.117468_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205449","article-title":"Anti-metastatic effect of metformin via repression of interleukin 6-induced epithelial\u2013mesenchymal transition in human colon cancer cells","volume":"13","author":"Kang","year":"2018","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.biopha.2024.117468_bib60","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/1759-7714.13328","article-title":"Targeting the PI3K\/Akt\/mTOR pathway in non-small cell lung cancer (NSCLC)","volume":"11","author":"Tan","year":"2020","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.biopha.2024.117468_bib61","article-title":"NF-\u03baB inhibitors in treatment and prevention of lung cancer","volume":"130","author":"Rasmi","year":"2020"},{"issue":"40","key":"10.1016\/j.biopha.2024.117468_bib62","doi-asserted-by":"crossref","first-page":"42667","DOI":"10.18632\/oncotarget.5626","article-title":"The Akt1\/IL-6\/STAT3 pathway regulates growth of lung tumor initiating cells","volume":"6","author":"Malanga","year":"2015","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.biopha.2024.117468_bib63","first-page":"2977","article-title":"Effect of targeted therapy with pazopanib on expression levels of transcription, growth factors and components of AKT\/m-TOR signaling pathway in patients with renal cell carcinoma","volume":"18","author":"Spirina","year":"2017","journal-title":"Asian Pac. J. Cancer Prev.: APJCP"},{"issue":"2","key":"10.1016\/j.biopha.2024.117468_bib64","doi-asserted-by":"crossref","first-page":"113","DOI":"10.12717\/DR.2020.24.2.113","article-title":"Antitumor activity of combination therapy with metformin and trametinib in non-small cell lung cancer cells","volume":"24","author":"Ko","year":"2020","journal-title":"Dev. Reprod."},{"issue":"6","key":"10.1016\/j.biopha.2024.117468_bib65","first-page":"1519","article-title":"Pazopanib and trametinib as a synergistic strategy against osteosarcoma: preclinical activity and molecular insights","volume":"12","author":"Chiabotto","year":"2020"},{"issue":"2","key":"10.1016\/j.biopha.2024.117468_bib66","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.18632\/oncotarget.13753","article-title":"Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.biopha.2024.117468_bib67","first-page":"2872","article-title":"Metformin and tenovin-6 synergistically induces apoptosis through LKB1-independent SIRT1 down-regulation in non-small cell lung cancer cells","volume":"23","author":"Lee","year":"2019"},{"issue":"55","key":"10.1016\/j.biopha.2024.117468_bib68","first-page":"93825","article-title":"Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction","volume":"8","author":"Chen","year":"2017"},{"issue":"1","key":"10.1016\/j.biopha.2024.117468_bib69","first-page":"8","article-title":"Antiproliferative action of metformin in human lung cancer cell lines","volume":"28","author":"Ashinuma","year":"2012","journal-title":"Oncol. Rep."},{"issue":"Suppl. 3","key":"10.1016\/j.biopha.2024.117468_bib70","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000088478","article-title":"VEGF as a key mediator of angiogenesis in cancer","volume":"69","author":"Carmeliet","year":"2005","journal-title":"Oncology"},{"issue":"10","key":"10.1016\/j.biopha.2024.117468_bib71","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1517\/14728222.2010.511617","article-title":"HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer","volume":"14","author":"Jackson","year":"2010","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.biopha.2024.117468_bib72","first-page":"1202","article-title":"Effects of pazopanib monotherapy vs. pazopanib and topotecan combination on anaplastic thyroid cancer cells","volume":"9","author":"Di Desidero","year":"2019"},{"issue":"2","key":"10.1016\/j.biopha.2024.117468_bib73","doi-asserted-by":"crossref","first-page":"131","DOI":"10.21873\/cgp.20173","article-title":"Pazopanib inhibits tumor growth, lymph-node metastasis and lymphangiogenesis of an orthotopic mouse of colorectal cancer","volume":"17","author":"Zhu","year":"2020","journal-title":"Cancer Genom. Proteom."},{"key":"10.1016\/j.biopha.2024.117468_bib74","first-page":"1636","article-title":"Additive antiproliferative and antiangiogenic effects of metformin and pemetrexed in a non-small-cell lung cancer xenograft model","author":"Wang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2024.117468_bib75","first-page":"1","article-title":"Cancer immunotherapy: present scenarios and the future of immunotherapy","author":"Chakraborty","year":"2019","journal-title":"Nucleus"},{"issue":"8","key":"10.1016\/j.biopha.2024.117468_bib76","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","author":"Alsaab","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117468_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2017.02.001","article-title":"Immune checkpoint inhibitors for patients with advanced non\u2013small-cell lung cancer: a systematic review","volume":"18","author":"Ellis","year":"2017","journal-title":"Clin. lung Cancer"},{"key":"10.1016\/j.biopha.2024.117468_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcancer.2017.12.002","article-title":"Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics","author":"Hegde","year":"2018","journal-title":"Semin. Cancer Biol."},{"issue":"11","key":"10.1016\/j.biopha.2024.117468_bib79","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.3390\/cancers12113129","article-title":"The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): which are the involved players?","volume":"12","author":"Lamberti","year":"2020","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.biopha.2024.117468_bib80","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159473","article-title":"Cross-talk between HIF and PD-1\/PD-L1 pathways in carcinogenesis and therapy","volume":"132","author":"Shurin","year":"2022","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.biopha.2024.117468_bib81","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.3934\/mbe.2020104","article-title":"High Expression of TLR2 in the serum of patients with tuberculosis and lung cancer, and can promote the progression of lung cancer","volume":"17","author":"Zhang","year":"2020","journal-title":"Math. Biosci. Eng."},{"issue":"6","key":"10.1016\/j.biopha.2024.117468_bib82","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1189\/jlb.1012501","article-title":"TLR agonists: our best frenemy in cancer immunotherapy","volume":"93","author":"Kaczanowska","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.biopha.2024.117468_bib83","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fimmu.2014.00083","article-title":"TLR agonists for cancer immunotherapy: tipping the balance between the immune stimulatory and inhibitory effects","volume":"5","author":"Lu","year":"2014","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117468_bib84","first-page":"296","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-\u03b3 and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood, J. Am. Soc. Hematol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117468_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010850","article-title":"Bacteria peptidoglycan promoted breast cancer cell invasiveness and adhesiveness by targeting toll-like receptor 2 in the cancer cells","volume":"5","author":"Xie","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2024.117468_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107101","article-title":"Roles of TGF-\u03b2 signaling pathway in tumor microenvirionment and cancer therapy.","volume":"89","author":"Zhao","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2024.117468_bib87","doi-asserted-by":"crossref","first-page":"9527","DOI":"10.2147\/OTT.S224013","article-title":"Blocking TGF-\u03b2 signaling to enhance the efficacy of immune checkpoint inhibitor.","volume":"12","author":"Bai","year":"2019","journal-title":"OncoTargets Ther."},{"issue":"6","key":"10.1016\/j.biopha.2024.117468_bib88","first-page":"711","article-title":"TK inhibitor pazopanib primes DCs by downregulation of the \u03b2-catenin pathway","volume":"6","author":"Zizzari","year":"2018"},{"issue":"7","key":"10.1016\/j.biopha.2024.117468_bib89","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00262-021-03116-x","article-title":"Metformin inhibits human non-small cell lung cancer by regulating AMPK\u2013CEBPB\u2013PDL1 signaling pathway","volume":"71","author":"Lu","year":"2022","journal-title":"Cancer Immunol., Immunother."},{"key":"10.1016\/j.biopha.2024.117468_bib90","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00210-015-1157-7","article-title":"The multi-kinase inhibitor pazopanib targets hepatic stellate cell activation and apoptosis alleviating progression of liver fibrosis","volume":"388","author":"Elshal","year":"2015","journal-title":"Naunyn-Schmiede's. Arch. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117468_bib91","first-page":"1495","article-title":"Metformin suppresses the invasive ability of pancreatic cancer cells by blocking autocrine TGF\u2011\u03b21 signaling","volume":"40","author":"Duan","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2024.117468_bib92","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1007\/s13277-015-4395-x","article-title":"Mechanism of metformin action in MCF-7 and MDA-MB-231 human breast cancer cells involves oxidative stress generation, DNA damage, and transforming growth factor \u03b21 induction","volume":"37","author":"Marinello","year":"2016","journal-title":"Tumor Biol."},{"issue":"9","key":"10.1016\/j.biopha.2024.117468_bib93","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1111\/cas.14124","article-title":"Effects of metformin and phenformin on apoptosis and epithelial-mesenchymal transition in chemoresistant rectal cancer","volume":"110","author":"Park","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2024.117468_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemosphere.2020.126526","article-title":"Identification and validation of metformin protects against PM2. 5-induced macrophages cytotoxicity by targeting toll like receptor pathway","volume":"251","author":"Shi","year":"2020","journal-title":"Chemosphere"},{"issue":"2","key":"10.1016\/j.biopha.2024.117468_bib95","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8+ T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2024.117468_bib96","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1002\/jcp.27782","article-title":"CD8+ cytotoxic T lymphocytes in cancer immunotherapy: a review","volume":"234","author":"Farhood","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.biopha.2024.117468_bib97","series-title":"Prognostic Role of Tumor-infiltrating Lymphocytes In Lung Cancer: A Meta-analysis","first-page":"1560","author":"Geng","year":"2015"},{"issue":"6","key":"10.1016\/j.biopha.2024.117468_bib98","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1073\/pnas.1417636112","article-title":"Immune-mediated antitumor effect by type 2 diabetes drug, metformin","volume":"112","author":"Eikawa","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2024.117468_bib99","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.117468_bib100","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-3-030-34461-0_18","article-title":"Hypoxia compromises anti-cancer immune responses","author":"Multhoff","year":"2020","journal-title":"Oxyg. Transp. Tissue XLI"},{"key":"10.1016\/j.biopha.2024.117468_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.05.002","article-title":"IFN-\u03b3: A cytokine at the right time, is in the right place","author":"Burke","year":"2019","journal-title":"Semin. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117468_bib102","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1089\/jir.2012.0110","article-title":"Interferons as inducers of apoptosis in malignant cells","volume":"33","author":"Kotredes","year":"2013","journal-title":"J. Interferon Cytokine Res."},{"issue":"5","key":"10.1016\/j.biopha.2024.117468_bib103","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005719","article-title":"Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression","volume":"11","author":"Finisguerra","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2024.117468_bib104","article-title":"Metformin synergizes with PD-L1 monoclonal antibody enhancing tumor immune response in treating non-small cell lung cancer and its molecular mechanism investigation","volume":"2022","author":"Wang","year":"2022"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224013544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224013544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:58:18Z","timestamp":1773968298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224013544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":104,"alternative-id":["S0753332224013544"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117468","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unveiling the antitumor synergy between pazopanib and metformin on lung cancer through suppressing p-Akt\/ NF-\u03baB\/ STAT3\/ PD-L1 signal pathway","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117468","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117468"}}